Overview

Ultra-high-sensitivity EGFR testing for the T790M resistance mutation alongside the L858R point mutation and exon 19 deletions supports treatment decisions in non-small cell lung cancer. The sensitizing changes - exon 19 deletions and L858R - activate EGFR and predict response to first- and second-generation EGFR tyrosine kinase inhibitors, while T790M is an acquired mutation that commonly emerges during treatment and drives resistance to those earlier agents. Identifying which patients need this test is as important as the test itself.

Which Patients Benefit Most

The clearest group are patients with advanced NSCLC who carry a sensitizing EGFR mutation and have progressed on a first- or second-generation EGFR inhibitor. In this setting, confirming T790M through a tissue re-biopsy or a blood-based liquid biopsy helps determine whether a third-generation EGFR inhibitor is appropriate. The ultra-high-sensitivity format matters because T790M may be present at low allele frequency, particularly in blood samples where tumor-derived DNA is diluted among normal DNA.

A second group is treatment-naive patients being assessed for any activating EGFR change, where detecting L858R or an exon 19 deletion at the outset establishes eligibility for EGFR-directed therapy. In both cases, the test refines rather than replaces pathology review and imaging.

Interpreting a Positive or Negative Result

A positive T790M result typically prompts a switch in the targeted agent class, while a negative result on blood testing may warrant a confirmatory tissue biopsy because tumor DNA shed into blood can be intermittent. Sensitizing mutations, when found, anchor the initial choice of inhibitor. Laboratories reporting these results should state the method, limit of detection, and whether the sample was tissue or plasma, since this context changes how confidently a negative can be acted upon.

For B2B buyers supplying molecular laboratories, the relevant procurement questions are analytical sensitivity, turnaround time, and validation against reference standards - not clinical claims.

FAQ

Q: What is the difference between T790M and the L858R or 19del changes? A: L858R and exon 19 deletions are sensitizing mutations that predict response to earlier EGFR inhibitors, whereas T790M is an acquired resistance mutation that usually appears during treatment.

Q: Why use a biopsy rather than only blood for T790M? A: Blood testing is less invasive, but tumor DNA shed can be intermittent; a negative blood result may need confirmation with a tissue biopsy.

Q: Who is the main candidate for this secondary test? A: Patients with EGFR-driven NSCLC who have progressed on a first- or second-generation EGFR inhibitor are the primary group that benefits from T790M assessment.

Q: Does finding an exon 19 deletion change first-line therapy? A: Yes, an exon 19 deletion or L858R result generally establishes eligibility for an EGFR-directed tyrosine kinase inhibitor as initial treatment.